Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01429064 · ClinicalTrials.gov registry record · Phase 2

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

A Phase 2 study of Prostate Cancer, sponsored by Orion Corporation, Orion Pharma.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target
17
Study locations

NCT01429064: Completed Phase 2 study of Prostate Cancer, sponsored by Orion Corporation, Orion Pharma.

NCT01429064 is a Phase 2 study of Prostate Cancer that has completed, run by Orion Corporation, Orion Pharma. The registered enrollment target is 76 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01429064, a Phase 2 study of Prostate Cancer, has completed, sponsored by Orion Corporation, Orion Pharma.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG ODM-201

Study Locations (17)

Other

  • Klinika onkologie a radioterapie LFUK a FN - Hradec Králové
  • East-Tallinn Central Hospital - Tallinn
  • Helsinki University Central Hospital - Helsinki
  • Kuopio University Hospital - Kuopio
  • Oulu University Hospital - Oulu
  • Tampere University Hospital - Tampere
  • Turku University Hospital - Turku
  • Saint Louis Hospital - Paris
  • Institut Gustave Roussy - Villejuif
  • Queen Elizabeth Hospital - Birmingham
  • Velindre Cancer Centre - Cardiff
  • Christie Hospital - Manchester
  • Churchill Hospital - Oxford

Colorado

  • The Urology Center of Colorado - Wheat Ridge

Connecticut

  • Eastern CT Hematology and Oncology Associates - Norwich

Ohio

  • Cleveland Clinic - Cleveland

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2011-06
Est. Completion 2015-11
Phase Phase 2

Sponsor

Orion Corporation, Orion Pharma

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01429064

The ClinicalTrials.gov registry entry for NCT01429064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Orion Corporation, Orion Pharma, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which ODM-201 is the first listed.

NCT01429064 reports 17 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01429064 about?

NCT01429064 is a clinical study titled "Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001". The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.

What is the current status of trial NCT01429064?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2011-06. Estimated completion is 2015-11.

What conditions does trial NCT01429064 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01429064?

The interventions under investigation include: ODM-201 (DRUG).

Who is sponsoring clinical trial NCT01429064?

This trial is sponsored by Orion Corporation, Orion Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01429064 being conducted?

This trial has 17 study locations across Colorado, Connecticut, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.